Clinical Trial Results:
Estudio internacional, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos, para investigar si Trovax, añadido al tratamiento estándar de primera linea, prolonga la supervivencia de pacientes con adenocarcinoma renal de células claras localmente avanzado o metastásico.
An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax®, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma.
Summary
|
|
EudraCT number |
2006-001246-13 |
Trial protocol |
ES DE GB |
Global completion date |
13 Mar 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Jan 2017
|
First version publication date |
06 Jan 2017
|
Other versions |
|
Summary report(s) |
TRIST TV3/001/06 CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.